Verona Pharma (VRNA) Projected to Post Quarterly Earnings on Thursday

Verona Pharma (NASDAQ:VRNA) will likely be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Verona Pharma to post earnings of ($0.23) per share and revenue of $26.49 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Verona Pharma Stock Down 3.5 %

VRNA stock opened at $65.60 on Tuesday. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. Verona Pharma has a 1 year low of $11.39 and a 1 year high of $68.64. The company has a fifty day simple moving average of $53.10 and a 200 day simple moving average of $40.04. The firm has a market cap of $5.28 billion, a PE ratio of -34.17 and a beta of 0.41.

Insiders Place Their Bets

In other news, CEO David Zaccardelli sold 98,888 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $5.01, for a total transaction of $495,428.88. Following the transaction, the chief executive officer now directly owns 15,078,624 shares in the company, valued at approximately $75,543,906.24. This represents a 0.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark W. Hahn sold 12,936 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $5.00, for a total transaction of $64,680.00. Following the transaction, the chief financial officer now owns 14,276,000 shares in the company, valued at $71,380,000. The trade was a 0.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 710,888 shares of company stock valued at $3,559,881. 4.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on VRNA shares. Wells Fargo & Company boosted their target price on shares of Verona Pharma from $64.00 to $74.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Roth Capital raised shares of Verona Pharma to a “strong-buy” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $60.00 price objective (up previously from $42.00) on shares of Verona Pharma in a report on Tuesday, January 21st. Truist Financial restated a “buy” rating and set a $57.00 price objective (up previously from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th. Finally, Roth Mkm initiated coverage on shares of Verona Pharma in a report on Friday, January 10th. They set a “buy” rating and a $68.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $57.14.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.